771 results on '"Solomon, Scott"'
Search Results
2. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
- Author
-
Kondo, Toru, Campbell, Ross, Jhund, Pardeep S., Anand, Inder S., Carson, Peter E., Lam, Carolyn S.P., Shah, Sanjiv J., Vaduganathan, Muthiah, Zannad, Faiez, Zile, Michael R., Solomon, Scott D., and McMurray, John J.V.
- Abstract
Although some patients with heart failure (HF) with mildly reduced/preserved ejection fraction have low natriuretic peptide levels, there are no large-scale systematic studies of how common these individuals are or what happens to them.
- Published
- 2024
- Full Text
- View/download PDF
3. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF
- Author
-
Gustafsson, Finn, Petrie, Mark C., Komtebedde, Jan, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G.F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Solomon, Scott D., and Shah, Sanjiv J.
- Abstract
The REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II) trial found that, compared with a sham procedure, the Corvia Atrial Shunt did not improve outcomes in heart failure with preserved or mildly reduced ejection fraction. However, after 12-month follow-up, “responders” (peak-exercise pulmonary vascular resistance <1.74 WU and absence of a cardiac rhythm management device) were identified.
- Published
- 2024
- Full Text
- View/download PDF
4. Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy
- Author
-
Kittipibul, Veraprapas, Vaduganathan, Muthiah, Ikeaba, Uchechukwu, Chiswell, Karen, Butler, Javed, DeVore, Adam D., Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., Linganathan, Karthik K., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C., and Greene, Stephen J.
- Abstract
Little is known regarding differences in cause-specific costs between heart failure (HF) with ejection fraction (EF) ≤40% vs >40%, and potential cost implications of sodium glucose co-transporter 2 inhibitor (SGLT2i) therapy.
- Published
- 2024
- Full Text
- View/download PDF
5. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
- Author
-
Apperloo, Ellen M, Neuen, Brendon L, Fletcher, Robert A, Jongs, Niels, Anker, Stefan D, Bhatt, Deepak L, Butler, Javed, Cherney, David Z I, Herrington, William G, Inzucchi, Silvio E, Jardine, Meg J, Liu, Chih-Chin, Mahaffey, Kenneth W, McGuire, Darren K, McMurray, John J V, Neal, Bruce, Packer, Milton, Perkovic, Vlado, Sabatine, Marc S, Solomon, Scott D, Staplin, Natalie, Szarek, Michael, Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zannad, Faiez, and Heerspink, Hiddo J L
- Abstract
SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists.
- Published
- 2024
- Full Text
- View/download PDF
6. Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure
- Author
-
Ostrominski, John W., Greene, Stephen J., Patel, Ravi B., Solomon, Nicole C., Chiswell, Karen, DeVore, Adam D., Butler, Javed, Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., Linganathan, Karthik K., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C., and Vaduganathan, Muthiah
- Abstract
IMPORTANCE: Kidney health has received increasing focus as part of comprehensive heart failure (HF) treatment efforts. However, the occurrence of clinically relevant kidney outcomes in contemporary populations with HF has not been well studied. OBJECTIVE: To examine rates of incident dialysis and acute kidney injury (AKI) among Medicare beneficiaries after HF hospitalization. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study evaluated adults aged 65 years or older who were hospitalized for HF across 372 sites in the Get With The Guidelines–Heart Failure registry in the US between January 1, 2014, and December 31, 2018. Patients younger than 65 years or requiring dialysis either during or prior to hospitalization were excluded. Data were analyzed from May 4, 2021, to March 8, 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was inpatient dialysis initiation in the year after HF hospitalization and was ascertained via linkage with Medicare claims data. Other all-cause and cause-specific hospitalizations were also evaluated. The covariate-adjusted association between discharge estimated glomerular filtration rate (eGFR) and 1-year postdischarge outcomes was examined using Cox proportional hazards regression models. RESULTS: Overall, among 85 298 patients included in the analysis (mean [SD] age, 80 [9] years; 53% women) mean (SD) left ventricular ejection fraction was 47% (16%) and mean (SD) eGFR was 53 (29) mL/min per 1.73 m2; 54 010 (63%) had an eGFR less than 60 mL/min per 1.73 m2. By 1 year after HF hospitalization, 6% had progressed to dialysis, 7% had progressed to dialysis or end-stage kidney disease, and 7% had been readmitted for AKI. Incident dialysis increased steeply with lower discharge eGFR category: compared with patients with an eGFR of 60 mL/min per 1.73 m2 or more, individuals with an eGFR of 45 to less than 60 and of less than 30 mL/min per 1.73 m2 had higher rates of dialysis readmission (45 to <60: adjusted hazard ratio [AHR], 2.16 [95% CI, 1.86-2.51]; <30: AHR, 28.46 [95% CI, 25.25-32.08]). Lower discharge eGFR (per 10 mL/min per 1.73 m2 decrease) was independently associated with a higher rate of readmission for dialysis (AHR, 2.23; 95% CI, 2.14-2.32), dialysis or end-stage kidney disease (AHR, 2.34; 95% CI, 2.24-2.44), and AKI (AHR, 1.25; 95% CI, 1.23-1.27), with similar findings for all-cause mortality, all-cause readmission, and HF readmission. Baseline left ventricular ejection fraction did not modify the covariate-adjusted association between lower discharge eGFR and kidney outcomes. CONCLUSIONS AND RELEVANCE: In this study, older adults with HF had substantial risk of kidney complications, with an estimated 6% progressing to dialysis in the year after HF hospitalization. These findings emphasize the need for health care approaches prioritizing kidney health in this high-risk population.
- Published
- 2024
- Full Text
- View/download PDF
7. Sex Differences in Heart Failure With Improved Ejection Fraction
- Author
-
Pabón, Maria A., Wang, Xiaowen, Lam, Carolyn S.P., O’Meara, Eileen, Vaduganathan, Muthiah, Claggett, Brian L., Foà, Alberto, Lu, Henri, Langkilde, Anna Maria, De Boer, Rudolf A., Desai, Akshay S., Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail N., Martinez, Felipe A., Shah, Sanjiv J., Petersson, Magnus, McMurray, John J.V., Solomon, Scott D., and Vardeny, Orly
- Published
- 2024
- Full Text
- View/download PDF
8. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial
- Author
-
Patel, Ravi B., Silvestry, Frank E., Komtebedde, Jan, Solomon, Scott D., Hasenfuß, Gerd, Litwin, Sheldon E., Borlaug, Barry A., Price, Matthew J., Kawash, Rami, Hummel, Scott L., Cutlip, Donald E., Leon, Martin B., van Veldhuisen, Dirk J., Rieth, Andreas J., McKenzie, Scott, Bugger, Heiko, Mazurek, Jeremy A., Kapadia, Samir R., Vanderheyden, Marc, Ky, Bonnie, and Shah, Sanjiv J.
- Abstract
IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status. DESIGN, SETTING, AND PARTICIPANTS: This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024. INTERVENTIONS: Atrial shunt device or sham control. MAIN OUTCOME MEASURES: Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure. RESULTS: The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, −5.65 mL; P <.001), left atrial (LA) minimal volume (mean difference, −2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P <.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P <.001) and right atrial (RA; mean difference, 9.71 mL; P <.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P <.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs −1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03088033
- Published
- 2024
- Full Text
- View/download PDF
9. Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial
- Author
-
Peikert, Alexander, Claggett, Brian L., Udell, Jacob A., Joseph, Jacob, Hegde, Sheila M., Kim, KyungMann, Mao, Lu, Wang, Tuo, Havighurst, Thomas C., Farkouh, Michael E., Bhatt, Deepak L., Tattersall, Matthew C., Cooper, Lawton S., Solomon, Scott D., and Vardeny, Orly
- Abstract
IMPORTANCE: High-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations in patients with high-risk cardiovascular disease in the INVESTED trial. Whether humoral immune response to influenza vaccine is associated with clinical outcomes is unknown. OBJECTIVE: To examine the antibody response to high-dose trivalent compared with standard-dose quadrivalent inactivated influenza vaccine and its associations with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis is a prespecified analysis of the immune response substudy of the randomized, double-blind, active-controlled INVESTED trial, which was conducted at 157 sites in the United States and Canada over 3 influenza seasons between September 2016 and January 2019. Antibody titers were determined by hemagglutination inhibition assays at randomization and 4 weeks during the 2017-2018 and 2018-2019 seasons. Eligibility criteria included recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor. Data were analyzed from February 2023 to June 2023. MAIN OUTCOMES AND MEASURES: Mean antibody titer change, seroprotection (antibody titer level ≥1:40) and seroconversion (≥4-fold increase in titer) at 4 weeks, and the association between seroconversion status and the risk for adverse clinical outcomes. INTERVENTIONS: High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine, with revaccination up to 3 seasons. RESULTS: Antibody data were available for 658 of 5260 randomized participants (12.5%; mean [SD] age, 66.2 [11.4] years; 507 male [77.1%], 151 female [22.9%]; 348 with heart failure [52.9%]). High-dose vaccine was associated with an increased magnitude in antibody titers for A/H1N1, A/H3N2, and B-type antigens compared with standard dose. More than 92% of all participants achieved seroprotection for each of the contained antigens, while seroconversion rates were higher in participants who received high-dose vaccine. Seroconversion for any antigen was not associated with the risk for cardiopulmonary hospitalizations or all-cause mortality (hazard ratio, 1.09; 95% CI, 0.79-1.53; P = .59), irrespective of randomized treatment (P = .38 for interaction). CONCLUSIONS AND RELEVANCE: High-dose vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02787044
- Published
- 2024
- Full Text
- View/download PDF
10. Daprodustat and Heart Failure in CKD
- Author
-
Cunningham, Jonathan W., Claggett, Brian L., Lopes, Renato D., McMurray, John J.V., Perkovic, Vlado, Carroll, Kevin, Hiemstra, Thomas, Khavandi, Kaivan, Lukas, Mary Ann, Ranganathan, Prerna, Shannon, Jennifer, van Adelsberg, Janet, Singh, Ajay K., and Solomon, Scott D.
- Published
- 2024
- Full Text
- View/download PDF
11. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
- Author
-
McDowell, Kirsty, Kondo, Toru, Talebi, Atefeh, Teh, Ken, Bachus, Erasmus, de Boer, Rudolf A., Campbell, Ross T., Claggett, Brian, Desai, Ashkay S., Docherty, Kieran F., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe, Simpson, Joanne, Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J. V.
- Abstract
IMPORTANCE: Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions. OBJECTIVE: To develop and validate a novel prediction model for clinical outcomes in patients with HFpEF using routinely collected variables and to compare it with a biomarker-driven approach. DESIGN, SETTING, AND PARTICIPANTS: Data were used from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial to derive the prediction model, and data from the Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction (PARAGON-HF) and the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trials were used to validate it. The outcomes were the composite of HF hospitalization (HFH) or cardiovascular death, cardiovascular death, and all-cause death. A total of 30 baseline candidate variables were selected in a stepwise fashion using multivariable analyses to create the models. Data were analyzed from January 2023 to June 2023. EXPOSURES: Models to estimate the 1-year and 2-year risk of cardiovascular death or hospitalization for heart failure, cardiovascular death, and all-cause death. RESULTS: Data from 6263 individuals in the DELIVER trial were used to derive the prediction model and data from 4796 individuals in the PARAGON-HF trial and 4128 individuals in the I-PRESERVE trial were used to validate it. The final prediction model for the composite outcome included 11 variables: N-terminal pro–brain natriuretic peptide (NT-proBNP) level, HFH within the past 6 months, creatinine level, diabetes, geographic region, HF duration, treatment with a sodium-glucose cotransporter 2 inhibitor, chronic obstructive pulmonary disease, transient ischemic attack/stroke, any previous HFH, and heart rate. This model showed good discrimination (C statistic at 1 year, 0.73; 95% CI, 0.71-0.75) in both validation cohorts (C statistic at 1 year, 0.71; 95% CI, 0.69-0.74 in PARAGON-HF and 0.75; 95% CI, 0.73-0.78 in I-PRESERVE) and calibration. The model showed similar discrimination to a biomarker-driven model including high-sensitivity cardiac troponin T and significantly better discrimination than the Meta-Analysis Global Group in Chronic (MAGGIC) risk score (C statistic at 1 year, 0.60; 95% CI, 0.58-0.63; delta C statistic, 0.13; 95% CI, 0.10-0.15; P < .001) and NT-proBNP level alone (C statistic at 1 year, 0.66; 95% CI, 0.64-0.68; delta C statistic, 0.07; 95% CI, 0.05-0.08; P < .001). Models derived for the prediction of all-cause and cardiovascular death also performed well. An online calculator was created to allow calculation of an individual’s risk. CONCLUSIONS AND RELEVANCE: In this prognostic study, a robust prediction model for clinical outcomes in HFpEF was developed and validated using routinely collected variables. The model performed better than NT-proBNP level alone. The model may help clinicians to identify high-risk patients and guide treatment decisions in HFpEF.
- Published
- 2024
- Full Text
- View/download PDF
12. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
- Author
-
McMurray, John J.V., Docherty, Kieran F., de Boer, Rudolf A., Hammarstedt, Ann, Kitzman, Dalane W., Kosiborod, Mikhail N., Maria Langkilde, Anna, Reicher, Barry, Senni, Michele, Shah, Sanjiv J., Wilderäng, Ulrica, Verma, Subodh, and Solomon, Scott D.
- Published
- 2024
- Full Text
- View/download PDF
13. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
- Author
-
Adamo, Marianna, Metra, Marco, Claggett, Brian L., Miao, Zi Michael, Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Solomon, Scott D., Biering-Sørensen, Tor, Divanji, Punag H., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.
- Abstract
Tricuspid regurgitation (TR) is common and is associated with poor outcomes in patients with heart failure (HF). However, data with adjudicated events from fully characterized patients with heart failure with reduced ejection fraction (HFrEF) are lacking.
- Published
- 2024
- Full Text
- View/download PDF
14. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
- Author
-
Dimond, Matthew G., Ibrahim, Nasrien E., Fiuzat, Mona, McMurray, John J.V., Lindenfeld, JoAnn, Ahmad, Tariq, Bozkurt, Biykem, Bristow, Michael R., Butler, Javed, Carson, Peter E., Felker, G. Michael, Jessup, Mariell, Murillo, Jaime, Kondo, Toru, Solomon, Scott D., Abraham, William T., O’Connor, Christopher M., and Psotka, Mitchell A.
- Abstract
Heart failure (HF) is a complex syndrome traditionally classified by left ventricular ejection fraction (LVEF) cutpoints. Although LVEF is prognostic for risk of events and predictive of response to some HF therapies, LVEF is a continuous variable and cutpoints are arbitrary, often based on historical clinical trial enrichment decisions rather than physiology. Holistic evaluation of the treatment effects for therapies throughout the LVEF range suggests the standard categorization paradigm for HF merits modification. The multidisciplinary Heart Failure Collaboratory reviewed data from large-scale HF clinical trials and found that many HF therapies have demonstrated therapeutic benefit across a large range of LVEF, but specific treatment effects vary across that range. Therefore, HF should practically be classified by association with an LVEF that is reduced or not reduced, while acknowledging uncertainty around the precise LVEF cutpoint, and future research should evaluate new therapies across the continuum of LVEF.
- Published
- 2024
- Full Text
- View/download PDF
15. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial
- Author
-
Vardeny, Orly, Desai, Akshay S., Jhund, Pardeep S., Fang, James C., Claggett, Brian, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe A., Shah, Sanjiv J., Mc Causland, Finnian R., Petrie, Mark C., Vaduganathan, Muthiah, McMurray, John J. V., and Solomon, Scott D.
- Abstract
IMPORTANCE: Heart failure with improved ejection fraction (HFimpEF), defined as prior left ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is understudied. OBJECTIVE: To examine mode of death and the association of dapagliflozin with reductions in cause-specific death in patients with HFimpEF. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial, conducted from August 2018 to December 2020. The trial randomly assigned patients with HF with LVEF greater than 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides to treatment with dapagliflozin (10 mg, once daily) or placebo. The presence of HFimpEF was captured through study case report forms. The primary outcome was a composite of worsening HF events (hospitalization or urgent HF visits) or cardiovascular death. Clinical outcomes were adjudicated by a blinded clinical end points committee. Data were analyzed from May 2022 to August 2023. INTERVENTION: Dapagliflozin vs placebo. MAIN OUTCOMES AND MEASURES: The mode of death in relation to HFimpEF status was examined, as well as the association of randomized treatment with cause-specific death in Cox regression models. RESULTS: Of 1151 patients with HFimpEF in DELIVER, 190 (16.5%) died, compared with 833 patients (16.3%) of 5112 with LVEF consistently greater than 40%. The overall distribution of mode of death was similar in those with HFimpEF compared with those with LVEF consistently greater than 40% (noncardiovascular death: 103 of 190 [54%] vs 428 of 833 [51%]; cardiovascular death: 87 of 190 [46%] vs 405 of 833 [49%], respectively). Most deaths in individuals with HFimpEF were noncardiovascular (103 of 180 [54%]). For cardiovascular deaths, sudden deaths were most common (36 of 190 events [19%]), followed by HF-related (29 of 190 events [15%]). Among patients with HFimpEF, treatment with dapagliflozin was associated with lower rates of cardiovascular death relative to placebo, a difference primarily due to lower rates of sudden death (hazard ratio, 0.38; 95% CI, 0.18-0.79; P for interaction = .01). CONCLUSIONS AND RELEVANCE: The findings in this study support current guideline recommendations for use of sodium-glucose transport protein 2 inhibitor therapy, and further suggest that the addition of a sodium-glucose transport protein 2 inhibitor therapy to other guideline-directed medical therapies may help reduce cardiovascular mortality in patients with HFimpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213
- Published
- 2024
- Full Text
- View/download PDF
16. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
- Author
-
Neuen, Brendon L., Heerspink, Hiddo J.L., Vart, Priya, Claggett, Brian L., Fletcher, Robert A., Arnott, Clare, de Oliveira Costa, Julianna, Falster, Michael O., Pearson, Sallie-Anne, Mahaffey, Kenneth W., Neal, Bruce, Agarwal, Rajiv, Bakris, George, Perkovic, Vlado, Solomon, Scott D., and Vaduganathan, Muthiah
- Published
- 2024
- Full Text
- View/download PDF
17. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
- Author
-
Mc Causland, Finnian R., Claggett, Brian L., Vaduganathan, Muthiah, Desai, Akshay, Jhund, Pardeep, Vardeny, Orly, Fang, James C., de Boer, Rudolf A., Docherty, Kieran F., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe, Saraiva, Jose F. Kerr, McGrath, Martina M., Shah, Sanjiv J., Verma, Subodh, Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J. V., and Solomon, Scott D.
- Abstract
IMPORTANCE: An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure. OBJECTIVE: To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of the results of the DELIVER randomized clinical trial, which was an international multicenter study of patients with EF greater than 40% and eGFR greater than or equal to 25. The DELIVER trial took place from August 2018 to March 2022. Data for the current prespecified study were analyzed from February to October 2023. INTERVENTION: Dapagliflozin, 10 mg per day, or placebo. MAIN OUTCOMES AND MEASURES: In this prespecified analysis, the frequency of an initial eGFR decline (baseline to month 1) was compared between dapagliflozin and placebo. Cox models adjusted for baseline eGFR and established prognostic factors were fit to estimate the association of an initial eGFR decline with cardiovascular (cardiovascular death or heart failure event) and kidney (≥50% eGFR decline, eGFR<15 or dialysis, death from kidney causes) outcomes, landmarked at month 1, stratified by diabetes. RESULTS: Study data from 5788 participants (mean [SD] age, 72 [10] years; 3253 male [56%]) were analyzed. The median (IQR) change in eGFR level from baseline to month 1 was −1 (−6 to 5) with placebo and −4 (−9 to 1) with dapagliflozin (difference, −3; P < .001). A higher proportion of patients assigned to dapagliflozin developed an initial eGFR decline greater than 10% vs placebo (1144 of 2892 [40%] vs 737 of 2896 [25%]; odds ratio, 1.9; 95% CI, 1.7-2.1; P difference <.001). An initial eGFR decline of greater than 10% (vs ≤10%) was associated with a higher risk of the primary cardiovascular outcome among those randomized to placebo (adjusted hazard ratio [aHR], 1.33; 95% CI, 1.10-1.62) but not among those randomized to dapagliflozin (aHR, 0.90; 95% CI, 0.74-1.09; P for interaction = .01). Similar associations were observed when alternative thresholds of initial eGFR decline were considered and when analyzed as a continuous measure. An initial eGFR decline of greater than 10% was not associated with adverse subsequent kidney composite outcomes in dapagliflozin-treated patients (aHR, 0.94; 95% CI, 0.49-1.82). CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213
- Published
- 2024
- Full Text
- View/download PDF
18. Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Cunningham, Jonathan W., Singh, Pulkit, Reeder, Christopher, Claggett, Brian, Marti-Castellote, Pablo M., Lau, Emily S., Khurshid, Shaan, Batra, Puneet, Lubitz, Steven A., Maddah, Mahnaz, Philippakis, Anthony, Desai, Akshay S., Ellinor, Patrick T., Vardeny, Orly, Solomon, Scott D., and Ho, Jennifer E.
- Abstract
IMPORTANCE: The gold standard for outcome adjudication in clinical trials is medical record review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication of medical records by natural language processing (NLP) may offer a more resource-efficient alternative but this approach has not been validated in a multicenter setting. OBJECTIVE: To externally validate the Community Care Cohort Project (C3PO) NLP model for heart failure (HF) hospitalization adjudication, which was previously developed and tested within one health care system, compared to gold-standard CEC adjudication in a multicenter clinical trial. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial, which compared 2 influenza vaccines in 5260 participants with cardiovascular disease at 157 sites in the US and Canada between September 2016 and January 2019. Analysis was performed from November 2022 to October 2023. EXPOSURES: Individual sites submitted medical records for each hospitalization. The central INVESTED CEC and the C3PO NLP model independently adjudicated whether the cause of hospitalization was HF using the prepared hospitalization dossier. The C3PO NLP model was fine-tuned (C3PO + INVESTED) and a de novo NLP model was trained using half the INVESTED hospitalizations. MAIN OUTCOMES AND MEASURES: Concordance between the C3PO NLP model HF adjudication and the gold-standard INVESTED CEC adjudication was measured by raw agreement, κ, sensitivity, and specificity. The fine-tuned and de novo INVESTED NLP models were evaluated in an internal validation cohort not used for training. RESULTS: Among 4060 hospitalizations in 1973 patients (mean [SD] age, 66.4 [13.2] years; 514 [27.4%] female and 1432 [72.6%] male]), 1074 hospitalizations (26%) were adjudicated as HF by the CEC. There was good agreement between the C3PO NLP and CEC HF adjudications (raw agreement, 87% [95% CI, 86-88]; κ, 0.69 [95% CI, 0.66-0.72]). C3PO NLP model sensitivity was 94% (95% CI, 92-95) and specificity was 84% (95% CI, 83-85). The fine-tuned C3PO and de novo NLP models demonstrated agreement of 93% (95% CI, 92-94) and κ of 0.82 (95% CI, 0.77-0.86) and 0.83 (95% CI, 0.79-0.87), respectively, vs the CEC. CEC reviewer interrater reproducibility was 94% (95% CI, 93-95; κ, 0.85 [95% CI, 0.80-0.89]). CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale.
- Published
- 2024
- Full Text
- View/download PDF
19. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
- Author
-
Abramson, Jeremy S., Palomba, M. Lia, Gordon, Leo I., Lunning, Matthew, Wang, Michael, Arnason, Jon, Purev, Enkhtsetseg, Maloney, David G., Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R., Ghosh, Nilanjan, Dehner, Christine, Kim, Yeonhee, Ogasawara, Ken, Kostic, Ana, and Siddiqi, Tanya
- Abstract
•Pivotal TRANSCEND NHL 001 study demonstrated the efficacy and safety of liso-cel as third-line or later treatment for patients with R/R LBCL.•With 2-year follow-up, liso-cel showed high response rates, durable remissions, and a manageable safety profile for patients with R/R LBCL.
- Published
- 2024
- Full Text
- View/download PDF
20. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials
- Author
-
Kondo, Toru, Jhund, Pardeep S., Gasparyan, Samvel B., Yang, Mingming, Claggett, Brian L., McCausland, Finnian R., Tolomeo, Paolo, Vadagunathan, Muthiah, Heerspink, Hiddo J. L., Solomon, Scott D., and McMurray, John J. V.
- Abstract
Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the combination of time-to-event and longitudinal measurements and taking into account the clinical importance of the components of composite outcomes, as well as their relative timing. We examined this approach in a post hoc analysis of two trials that compared dapagliflozin to placebo in patients with heart failure and reduced ejection fraction (DAPA-HF) and mildly reduced or preserved ejection fraction (DELIVER). The effect of dapagliflozin on a hierarchical composite kidney outcome was assessed, including the following: (1) all-cause mortality; (2) end-stage kidney disease; (3) a decline in estimated glomerular filtration rate (eGFR) of ≥57%; (4) a decline in eGFR of ≥50%; (5) a decline in eGFR of ≥40%; and (6) participant-level eGFR slope. For this outcome, the win ratio was 1.10 (95% confidence interval (CI) = 1.06–1.15) in the combined dataset, 1.08 (95% CI = 1.01–1.16) in the DAPA-HF trial and 1.12 (95% CI = 1.05–1.18) in the DELIVER trial; that is, dapagliflozin was superior to placebo in both trials. The benefits of treatment were consistent in participants with and without baseline kidney disease, and with and without type 2 diabetes. In heart failure trials, win statistics may provide the statistical power to evaluate the effect of treatments on kidney as well as cardiovascular outcomes.
- Published
- 2024
- Full Text
- View/download PDF
21. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
- Author
-
Lee, Matthew M Y, Kondo, Toru, Campbell, Ross T, Petrie, Mark C, Sattar, Naveed, Solomon, Scott D, Vaduganathan, Muthiah, Jhund, Pardeep S, and McMurray, John J V
- Abstract
Graphical AbstractAre RAS blockers (ACE inhibitors and ARBs) safe in COVID-19 infection?
- Published
- 2024
- Full Text
- View/download PDF
22. HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation
- Author
-
Solh, Melhem, Aubrey, Michael T., Zhang, Xu, Bashey, Asad, Freed, Brian M., Roark, Christina L., Bachier-Rdriguez, Lizamarie, Morris, Lawrence E., Kent Holland, H., and Solomon, Scott R.
- Abstract
Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single individual can dictate the ability to present TAAs. The impact of HED in haploidentical donor transplantation (HIDT) has not been studied. We studied the effect of HED on transplant outcomes following HIDT. We analyzed 322 consecutive recipient/donor pairs with a median follow-up of 57.2 months. Pairwise divergence of HLA class I and II showed that HLA-B, -DRB1, and -DQB1 contributing most to mean HED. The mean HED was class I 6.85 (HLA-A 7.08, -B 8.24, and -C 5.07), class II 8.58 (HLA-DRB1 10.97, -DQB1 10.06 and -DPB1 4.06). A high HED in class I mismatched recipient/donor haplotype (RD MM) was significant for worse DFS (HR 1.11, p= 0.020), and relapse (HR 1.11, p= 0.02). Also, a high HED in RD MM HLA-B haplotype had worse OS (HR 1.07, p= 0.02), DFS (HR 1.09, p= 0.002), higher relapse (HR 1.10, p= 0.003), and similar NRM to low HED. The multivariate analysis showed that high HED in RD MM HLA-B (≥7.8 vs <7.8) had worse DFS (HR 1.53, p= 0.01), higher relapse (HR 1.61, p= 0.024), and similar NRM and OS.
- Published
- 2024
- Full Text
- View/download PDF
23. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
- Author
-
Lala, Anuradha, Hamo, Carine E., Bozkurt, Biykem, Fiuzat, Mona, Blumer, Vanessa, Bukhoff, Daniel, Butler, Javed, Costanzo, Maria Rosa, Felker, G. Michael, Filippatos, Gerasimos, Konstam, Marvin A., McMurray, John J.V., Mentz, Robert J., Metra, Marco, Psotka, Mitchell A., Solomon, Scott D., Teerlink, John, Abraham, William T., and O’Connor, Christopher M.
- Abstract
Acute decompensated heart failure (ADHF) is one of the most common reasons for hospitalizations or urgent care and is associated with poor outcomes. Therapies shown to improve outcomes are limited, however, and innovation in pharmacologic and device-based therapeutics are therefore actively being sought. Standardizing definitions for ADHF and its trajectory is complex, limiting the generalizability and translation of clinical trials to effect clinical care and policy change. The Heart Failure Collaboratory is a multistakeholder organization comprising clinical investigators, clinicians, patients, government representatives (including U.S. Food and Drug Administration and National Institutes of Health participants), payors, and industry collaborators. The following expert consensus document is the product of the Heart Failure Collaboratory convening with the Academic Research Consortium, including members from academia, the U.S. Food and Drug Administration, and industry, for the purposes of proposing standardized definitions for ADHF and highlighting important endpoint considerations to inform the design and conduct of clinical trials for drugs and devices in this clinical arena.
- Published
- 2024
- Full Text
- View/download PDF
24. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
- Author
-
Ostrominski, John W., Vaduganathan, Muthiah, Selvaraj, Senthil, Claggett, Brian L., Miao, Zi Michael, Desai, Akshay S., Jhund, Pardeep S., Kosiborod, Mikhail N., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Petersson, Magnus, Maria Langkilde, Anna, McMurray, John J.V., and Solomon, Scott D.
- Published
- 2023
- Full Text
- View/download PDF
25. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
- Author
-
Pabon, Maria, Cunningham, Jon, Claggett, Brian, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Diaz, Rafael, Wang, Xiaowen, Arias-Mendoza, Alexandra, Bonderman, Diana, Crespo-Leiro, Maria, Fonseca, Cândida, Goncalvesova, Eva, Lund, Mayanna, O’Meara, Eileen, Sliwa-Hahnle, Karen, Malik, Fady I., Solomon, Scott D., and Teerlink, John R.
- Abstract
Women with heart failure with reduced ejection fraction (HFrEF) receive less guideline-recommended therapy and experience worse quality of life than men.
- Published
- 2023
- Full Text
- View/download PDF
26. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
- Author
-
Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.
- Abstract
•Age of >60 years and remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS.•Use of myeloablative conditioning with total body irradiation was predictive for improved DFS and reduced risk of relapse.
- Published
- 2023
- Full Text
- View/download PDF
27. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
- Author
-
Bhatt, Ankeet S., Vaduganathan, Muthiah, Claggett, Brian L., Fonarow, Gregg C., Packer, Milton, Pfeffer, Marc A., Shah, Sanjiv J., Shen, Xian, Cristino, Joaquim, McMurray, John J. V., Solomon, Scott D., and Gaziano, Thomas A.
- Abstract
IMPORTANCE: The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those with below-normal EF. However, the upper bound of below normal is not clearly defined, and value determinations across a broader EF range are unknown. OBJECTIVE: To estimate the cost-effectiveness of sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) across various upper-level cutoffs of EF. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included participant-level data from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and the PARAGON-HF (Prospective Comparison of ARNi with ARB Global Outcomes in HF With Preserved Ejection Fraction) trials. PARADIGM-HF was conducted between 2009 and 2014, PARAGON-HF was conducted between 2014 and 2019, and this analysis was conducted between 2021 and 2023. MAIN OUTCOMES AND MEASURES: A 5-state Markov model used risk reductions for all-cause mortality and HF hospitalization from PARADIGM-HF and PARAGON-HF. Quality-of-life differences were estimated from EuroQol-5D scores. Hospitalization and medication costs were obtained from published national sources; the wholesale acquisition cost of sacubitril-valsartan was $7092 per year. Risk estimates and treatment effects were generated in consecutive 5% EF increments up to 60% and applied to an EF distribution of US patients with HF from the Get With the Guidelines–Heart Failure registry. The base case included a lifetime horizon from a health care sector perspective. Incremental cost-effectiveness ratios (ICERs) were estimated at EFs of 60% or less (base case) and at various upper-level EF cutoffs. RESULTS: Among 13 264 total patients whose data were analyzed, for those with EFs of 60% or less, sacubitril-valsartan was projected to add 0.53 quality-adjusted life-years (QALYs) at an incremental lifetime cost of $40 892 compared with RASi, yielding an ICER of $76 852 per QALY. In a probabilistic sensitivity analysis, 95% of the values of the ICER occurred between $71 516 and $82 970 per QALY. Among patients with chronic HF and an EF of 60% or less, treatment with sacubitril-valsartan vs RASis would be at least of economic intermediate value (ICER <$180 000 per QALY) at a sacubitril-valsartan cost of $10 242 or less per year, of high economic value (ICER <$60 000 per QALY) at a cost of $3673 or less per year, and cost-saving at a cost of $338 or less per year. The ICERs were $67 331 per QALY, $59 614 per QALY, and $56 786 per QALY at EFs of 55% or less, 50% or less, and 45% or less, respectively. Treatment with sacubitril-valsartan in only those with EFs of 45% or greater (up to ≤60%) yielded an ICER of $127 172 per QALY gained; treatment was more cost-effective in those at the lower end of this range (ICER of $100 388 per QALY gained for those with EFs of 45%-55%; ICER of $84 291 per QALY gained for those with EFs of 45%-50%). CONCLUSIONS AND RELEVANCE: Cost-effectiveness modeling provided an ICER for treatment with sacubitril-valsartan vs RASis consistent with high economic value for patients with reduced and mildly reduced EFs (≤50%) and at least intermediate value at the current undiscounted wholesale acquisition cost price at an EF of 60% or less. Treatment was more cost-effective at lower EF ranges. These findings may have implications for coverage decisions and value assessments in contemporary clinical practice guidelines.
- Published
- 2023
- Full Text
- View/download PDF
28. Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial
- Author
-
Vissing, Christoffer Rasmus, Axelsson Raja, Anna, Day, Sharlene M., Russell, Mark W., Zahka, Kenneth, Lever, Harry M., Pereira, Alexandre C., Colan, Steven D., Margossian, Renee, Murphy, Anne M., Canter, Charles, Bach, Richard G., Wheeler, Matthew T., Rossano, Joseph W., Owens, Anjali T., Benson, Lee, Mestroni, Luisa, Taylor, Matthew R. G., Patel, Amit R., Wilmot, Ivan, Thrush, Philip, Soslow, Jonathan H., Becker, Jason R., Seidman, Christine E., Lakdawala, Neal K., Cirino, Allison L., McMurray, John J. V., MacRae, Calum A., Solomon, Scott D., Bundgaard, Henning, Orav, E. John, and Ho, Carolyn Y.
- Abstract
IMPORTANCE: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E′ velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022. INTERVENTIONS: Treatment with placebo or valsartan (80 mg/d for children weighing <35 kg, 160 mg/d for children weighing ≥35 kg, or 320 mg/d for adults aged ≥18 years). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite z score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E′ velocity and S′ velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels). RESULTS: This study included 34 participants, with a mean (SD) age of 16 (5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite z score compared with placebo: −0.01 [95% CI, −0.29 to 0.26]; P = .92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL/m2 [95% CI, 1.4-6.0 mL/m2]; P = .002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL/m2; P = .01) and average interventricular septum thickness (8.5 vs 7.0 mm; P = .009) were higher in participants who developed HCM. CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534
- Published
- 2023
- Full Text
- View/download PDF
29. Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction
- Author
-
Patel, Ravi B., Reddy, Vivek Y., Komtebedde, Jan, Wegerich, Stephan W., Sekaric, Jadranka, Swarup, Vijay, Walton, Antony, Laurent, Gabriel, Chetcuti, Stanley, Rademann, Matthias, Bergmann, Martin, McKenzie, Scott, Bugger, Heiko, Bruno, Raphael Romano, Herrmann, Howard C., Nair, Ajith, Gupta, Deepak K., Lim, Scott, Kapadia, Samir, Gordon, Robert, Vanderheyden, Marc, Noel, Thomas, Bailey, Steven, Gertz, Zachary M., Trochu, Jean-Noël, Cutlip, Donald E., Leon, Martin B., Solomon, Scott D., van Veldhuisen, Dirk J., Auricchio, Angelo, and Shah, Sanjiv J.
- Abstract
Atrial fibrillation (AF) is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF) and in heart failure with mildly reduced ejection fraction (HFmrEF).
- Published
- 2023
- Full Text
- View/download PDF
30. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
- Author
-
Butt, Jawad H., Docherty, Kieran F., Kosiborod, Mikhail N., Inzucchi, Silvio E., Køber, Lars, Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott, Jhund, Pardeep S., and McMurray, John J.V.
- Abstract
Heart failure (HF) is associated with impaired physical function and poor quality of life and affects health status more profoundly than many other chronic diseases.
- Published
- 2023
- Full Text
- View/download PDF
31. Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
- Author
-
Solomon, Scott R., Solh, Melhem, Morris, Lawrence E., Holland, H. Kent, Bachier-Rodriguez, Lizamarie, Zhang, Xu, Guzowski, Caitlin, Jackson, Katelin C, Brown, Stacey, and Bashey, Asad
- Abstract
•Pembrolizumab after autologous transplant is safe and effective, with low nonrelapse mortality and 2-year OS and LFS and OS of 68% and 48%.•In patients with nonfavorable risk AML, OS was comparable for propensity score–matched patients receiving an allogeneic transplant.
- Published
- 2023
- Full Text
- View/download PDF
32. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
- Author
-
Kondo, Toru, Dewan, Pooja, Anand, Inder S., Desai, Akshay S., Packer, Milton, Zile, Michael R., Pfeffer, Marc A., Solomon, Scott D., Abraham, William T., Shah, Sanjiv J., Lam, Carolyn S.P., Jhund, Pardeep S., and McMurray, John J.V.
- Published
- 2023
- Full Text
- View/download PDF
33. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
- Author
-
Siddiqi, Tanya, Maloney, David G, Kenderian, Saad S, Brander, Danielle M, Dorritie, Kathleen, Soumerai, Jacob, Riedell, Peter A, Shah, Nirav N, Nath, Rajneesh, Fakhri, Bita, Stephens, Deborah M, Ma, Shuo, Feldman, Tatyana, Solomon, Scott R, Schuster, Stephen J, Perna, Serena K, Tuazon, Sherilyn A, Ou, San-San, Papp, Eniko, Peiser, Leanne, Chen, Yizhe, and Wierda, William G
- Abstract
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Published
- 2023
- Full Text
- View/download PDF
34. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
- Author
-
Bashey, Asad, Zhang, Xu, Morris, Lawrence E., Holland, H. K., Bachier-Rodriguez, Lizamarie, Solomon, Scott R., and Solh, Melhem
- Abstract
•Close integration of leukemia and HCT services and the use of haploidentical donors result in greater access to HCT than previously reported.•Racial disparity is reduced by this approach, but caregiver requirements continue to limit HCT access for Black patients.
- Published
- 2023
- Full Text
- View/download PDF
35. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
- Author
-
Litwin, Sheldon E., Komtebedde, Jan, Hu, Mo, Burkhoff, Daniel, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Gorter, Thomas M., Demers, Catherine, Shetty, Ranjith, Lewis, Gregory, Starling, Randall C., Patel, Sanjay, Gupta, Deepak K., Morsli, Hakim, Penicka, Martin, Cikes, Maja, Gustafsson, Finn, Silvestry, Frank E., Rowin, Ethan J., Cutlip, Donald E., Leon, Martin B., Kitzman, Dalane W., Kleber, Franz X., and Shah, Sanjiv J.
- Abstract
Many patients with heart failure and preserved ejection fraction have no overt volume overload and normal resting left atrial (LA) pressure.
- Published
- 2023
- Full Text
- View/download PDF
36. Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
- Author
-
Solomon, Scott D., Lowenstein, Charles J., Bhatt, Ankeet S., Peikert, Alexander, Vardeny, Orly, Kosiborod, Mikhail N., Berger, Jeffrey S., Reynolds, Harmony R., Mavromichalis, Stephanie, Barytol, Anya, Althouse, Andrew D., Luther, James F., Leifer, Eric S., Kindzelski, Andrei L., Cushman, Mary, Gong, Michelle N., Kornblith, Lucy Z., Khatri, Pooja, Kim, Keri S., Baumann Kreuziger, Lisa, Wahid, Lana, Kirwan, Bridget-Anne, Geraci, Mark W., Neal, Matthew D., and Hochman, Judith S.
- Published
- 2023
- Full Text
- View/download PDF
37. Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US
- Author
-
Selvaraj, Senthil, Claggett, Brian L., Quarta, C. Cristina, Yu, Bing, Inciardi, Riccardo M., Buxbaum, Joel N., Mosley, Thomas H., Shah, Amil M., Dorbala, Sharmila, Falk, Rodney H., and Solomon, Scott D.
- Abstract
IMPORTANCE: Hereditary transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure (HF) with distinct treatment. The amyloidogenic pV142I (V122I) variant is present in 3% to 4% of Black individuals in the US and increases the risk for atrial fibrillation (AF), HF, and mortality. Since hereditary transthyretin cardiac amyloidosis demonstrates age-dependent anatomic penetrance, evaluation later in life may identify survivors at particularly high risk. OBJECTIVE: To estimate age-dependent risks for cardiovascular events with the variant. DESIGN, SETTINGS, AND PARTICIPANTS: This cohort study analyzed Black participants from the Atherosclerosis Risk in Communities (ARIC) study attending visit 1 (1987-1989) (followed up until 2019; median follow-up, 27.6 years). Data analyses were completed from June 2022 to April 2023. EXPOSURE: pV142I carrier status. MAIN OUTCOMES: The association between the variant and AF, HF hospitalization, mortality, and a composite of HF hospitalization or mortality was modeled by generating 10-year absolute risk differences for each year between ages 53 (the median age at visit 1) and 80 years, adjusting for the first 5 principal components of ancestry and sex. As an example, 5- and 10-year risk differences were specifically estimated for the composite outcome among participants surviving to age 80 years. RESULTS: Among 3856 Black participants (including 124 carriers) at visit 1, 2403 (62%) were women, 2140 (56%) had hypertension, and 740 (20%) had diabetes, with no differences between groups. The 10-year absolute risk difference between ages 53 and 80 years increased over time for each outcome. Statistical significance for increased 10-year risk difference emerged near ages 65 years for AF, 70 years for HF hospitalization, and 75 years for mortality. Among participants surviving to age 80 years, carriers had a 20% (95% CI, 2%-37%) and 24% (95% CI, 1%-47%) absolute increased risk for HF hospitalization or death at 5 and 10 years, respectively. Thus, at age 80 years, only 4 carriers would need to be identified to attribute 1 HF hospitalization or death over the following decade to the variant. CONCLUSIONS AND RELEVANCE: In this study, age-specific risks were provided for relevant outcomes with the pV142I variant. Despite a relatively benign course during earlier years, Black individuals who carry the pV142I variant surviving into later life may be particularly vulnerable. These data may inform timing for screening, risk counseling to patients, and potential strategies for early targeted therapy.
- Published
- 2023
- Full Text
- View/download PDF
38. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
- Author
-
Peikert, Alexander, Chandra, Alvin, Kosiborod, Mikhail N., Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Janssens, Stefan P., Belohlávek, Jan, Borleffs, C. Jan Willem, Dobreanu, Dan, Langkilde, Anna Maria, Bengtsson, Olof, Petersson, Magnus, McMurray, John J. V., Solomon, Scott D., and Vaduganathan, Muthiah
- Abstract
IMPORTANCE: Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. A comprehensive understanding of the responsiveness of individual KCCQ items would allow clinicians to better inform patients on expected changes in daily living with treatment. OBJECTIVE: To examine the association of dapagliflozin treatment with changes in individual components of the KCCQ. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc exploratory analysis of DELIVER, a randomized double-blind placebo-controlled trial conducted at 353 centers in 20 countries from August 2018 to March 2022. KCCQ was administered at randomization and 1, 4, and 8 months. Scores of individual KCCQ components were scaled from 0 to 100. Eligibility criteria included symptomatic HF with left ventricular ejection fraction greater than 40%, elevated natriuretic peptide levels, and evidence of structural heart disease. Data were analyzed from November 2022 to February 2023. MAIN OUTCOMES AND MEASURES: Changes in the 23 individual KCCQ components at 8 months. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or placebo. RESULTS: Baseline KCCQ data were available for 5795 of 6263 randomized patients (92.5%) (mean [SD] age, 71.5 [9.5] years; 3344 male [57.7%] and 2451 female [42.3%]). Dapagliflozin was associated with larger improvements in almost all KCCQ components at 8 months compared with placebo. The most significant improvements with dapagliflozin were observed in frequency of lower limb edema (difference, 3.2; 95% CI, 1.6-4.8; P < .001), sleep limitation by shortness of breath (difference, 3.0; 95% CI, 1.6-4.4; P < .001), and limitation in desired activities by shortness of breath (difference, 2.8; 95% CI, 1.3-4.3; P < .001). Similar treatment patterns were observed in longitudinal analyses integrating data from months 1, 4, and 8. Higher proportions of patients treated with dapagliflozin experienced improvements, and fewer had deteriorations across most individual components. CONCLUSIONS AND RELEVANCE: In this study of patients with HF with mildly reduced or preserved ejection fraction, dapagliflozin was associated with improvement in a broad range of individual KCCQ components, with the greatest benefits in domains related to symptom frequency and physical limitations. Potential improvements in specific symptoms and activities of daily living might be more readily recognizable and easily communicated to patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213
- Published
- 2023
- Full Text
- View/download PDF
39. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines–Heart Failure Registry
- Author
-
Pierce, Jacob B., Vaduganathan, Muthiah, Fonarow, Gregg C., Ikeaba, Uchechukwu, Chiswell, Karen, Butler, Javed, DeVore, Adam D., Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., Linganathan, Karthik K., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., and Greene, Stephen J.
- Abstract
IMPORTANCE: Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i for HFrEF in the US is unknown. OBJECTIVE: To characterize patterns of SGLT2i use among eligible US patients hospitalized for HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed 49 399 patients hospitalized for HFrEF across 489 sites in the Get With The Guidelines–Heart Failure (GWTG-HF) registry between July 1, 2021, and June 30, 2022. Patients with an estimated glomerular filtration rate less than 20 mL/min/1.73 m2, type 1 diabetes, and previous intolerance to SGLT2i were excluded. MAIN OUTCOMES AND MEASURES: Patient-level and hospital-level prescription of SGLT2i at hospital discharge. RESULTS: Of 49 399 included patients, 16 548 (33.5%) were female, and the median (IQR) age was 67 (56-78) years. Overall, 9988 patients (20.2%) were prescribed an SGLT2i. SGLT2i prescription was less likely among patients with chronic kidney disease (CKD; 4550 of 24 437 [18.6%] vs 5438 of 24 962 [21.8%]; P < .001) but more likely among patients with type 2 diabetes (T2D; 5721 of 21 830 [26.2%] vs 4262 of 27 545 [15.5%]; P < .001) and those with both T2D and CKD (2905 of 12 236 [23.7%] vs 7078 vs 37 139 [19.1%]; P < .001). Patients prescribed SGLT2i therapy were more likely to be prescribed background triple therapy with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β-blocker, and mineralocorticoid receptor antagonist (4624 of 9988 [46.3%] vs 10 880 of 39 411 [27.6%]; P < .001), and 4624 of 49 399 total study patients (9.4%) were discharged with prescriptions for quadruple medical therapy including SGLT2i. Among 461 hospitals with 10 or more eligible discharges, 19 hospitals (4.1%) discharged 50% or more of patients with prescriptions for SGLT2i, whereas 344 hospitals (74.6%) discharged less than 25% of patients with prescriptions for SGLT2i (including 29 [6.3%] that discharged zero patients with SGLT2i prescriptions). There was high between-hospital variance in the rate of SGLT2i prescription in unadjusted models (median odds ratio, 2.53; 95% CI, 2.36-2.74) and after adjustment for patient and hospital characteristics (median odds ratio, 2.51; 95% CI, 2.34-2.71). CONCLUSIONS AND RELEVANCE: In this study, prescription of SGLT2i at hospital discharge among eligible patients with HFrEF was low, including among patients with comorbid CKD and T2D who have multiple indications for therapy, with substantial variation among US hospitals. Further efforts are needed to overcome implementation barriers and improve use of SGLT2i among patients with HFrEF.
- Published
- 2023
- Full Text
- View/download PDF
40. Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan
- Author
-
Mohebi, Reza, Liu, Yuxi, Myhre, Peder L., Felker, G. Michael, Prescott, Margaret F., Piña, Ileana L., Butler, Javed, Ward, Jonathan H., Solomon, Scott D., and Januzzi, James L.
- Published
- 2023
- Full Text
- View/download PDF
41. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
- Author
-
Curtain, James P., Adamson, Carly, Docherty, Kieran F., Jhund, Pardeep S., Desai, Akshay S., Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Swedberg, Karl, Zile, Michael R., Solomon, Scott D., Packer, Milton, and McMurray, John J.V.
- Abstract
Anemia is common in patients with heart failure with reduced ejection fraction and is associated with poor clinical outcomes. Renin-angiotensin system blockers lower hemoglobin and may induce anemia.
- Published
- 2023
- Full Text
- View/download PDF
42. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
- Author
-
Jhund, Pardeep S., Claggett, Brian L., Talebi, Atefeh, Butt, Jawad H., Gasparyan, Samvel B., Wei, Lee-Jen, McCaw, Zachary R., Wilderäng, Ulrica, Bengtsson, Olof, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe A., Shah, Sanjiv J., Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J. V.
- Abstract
IMPORTANCE: In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved ejection fraction (EF). OBJECTIVE: To evaluate the effect of dapagliflozin on total (ie, first and recurrent) HF events and cardiovascular death in this population. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified analysis of the DELIVER trial, the proportional rates approach of Lin, Wei, Yang, and Ying (LWYY) and a joint frailty model were used to examine the effect of dapagliflozin on total HF events and cardiovascular death. Several subgroups were examined to test for heterogeneity in the effect of dapagliflozin, including left ventricular EF. Participants were enrolled from August 2018 to December 2020, and data were analyzed from August to October 2022. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or matching placebo. MAIN OUTCOMES AND MEASURES: The outcome was total episodes of worsening HF (hospitalization for HF or urgent HF visit requiring intravenous HF therapies) and cardiovascular death. RESULTS: Of 6263 included patients, 2747 (43.9%) were women, and the mean (SD) age was 71.7 (9.6) years. There were 1057 HF events and cardiovascular deaths in the placebo group compared with 815 in the dapagliflozin group. Patients with more HF events had features of more severe HF, such as higher N-terminal pro–B-type natriuretic peptide level, worse kidney function, more prior HF hospitalizations, and longer duration of HF, although EF was similar to those with no HF events. In the LWYY model, the rate ratio for total HF events and cardiovascular death for dapagliflozin compared with placebo was 0.77 (95% CI, 0.67-0.89; P < .001) compared with a hazard ratio of 0.82 (95% CI, 0.73-0.92; P < .001) in a traditional time to first event analysis. In the joint frailty model, the rate ratio was 0.72 (95% CI, 0.65-0.81; P < .001) for total HF events and 0.87 (95% CI, 0.72-1.05; P = .14) for cardiovascular death. The results were similar for total HF hospitalizations (without urgent HF visits) and cardiovascular death and in all subgroups, including those defined by EF. CONCLUSIONS AND RELEVANCE: In the DELIVER trial, dapagliflozin reduced the rate of total HF events (first and subsequent HF hospitalizations and urgent HF visits) and cardiovascular death regardless of patient characteristics, including EF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213
- Published
- 2023
- Full Text
- View/download PDF
43. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
- Author
-
Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.
- Published
- 2023
- Full Text
- View/download PDF
44. Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial
- Author
-
Modin, Daniel, Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Bhatt, Ankeet S., Lee, Simin Gharib, Claggett, Brian L., Dueger, Erica L., Samson, Sandrine I., Loiacono, Matthew M., Køber, Lars, Solomon, Scott D., Sivapalan, Pradeesh, Jensen, Jens Ulrik Stæhr, Jean-Marie Martel, Cyril, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor
- Published
- 2023
- Full Text
- View/download PDF
45. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction
- Author
-
Lanfear, David E., Njoroge, Joyce N., Adams, Kirkwood F., Anand, Inder, Fang, James C., Ramires, Felix, Sliwa-Hahnle, Karen, Badat, Aysha, Burgess, Lesley, Gorodeski, Eiran Z., Williams, Celeste, Diaz, Rafael, Felker, Gary M., McMurray, John J.V., Metra, Marco, Solomon, Scott, Miao, Zi Michael, Claggett, Brian L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.
- Abstract
Omecamtiv mecarbil improves cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). Consistency of drug benefit across race is a key public health topic.
- Published
- 2023
- Full Text
- View/download PDF
46. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
- Author
-
Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali
- Abstract
This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor–positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.
- Published
- 2023
- Full Text
- View/download PDF
47. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial
- Author
-
Kondo, Toru, Jering, Karola S., Borleffs, C. Jan Willem, de Boer, Rudolf A., Claggett, Brian L., Desai, Akshay S., Dobreanu, Dan, Inzucchi, Silvio E., Hernandez, Adrian F., Janssens, Stefan P., Jhund, Pardeep S., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Martinez, Felipe A., Petersson, Magnus, Vinh, Pham Nguyen, Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J.V.
- Published
- 2023
- Full Text
- View/download PDF
48. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
- Author
-
Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Fang, James C., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Cabrera Honorio, Jose Walter, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S.P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Vardeny, Orly, O'Meara, Eileen, Saraiva, Jose F.K., Shah, Sanjiv J., Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J.V.
- Abstract
Black people have a higher incidence and prevalence of heart failure (HF) than White people, and once HF has developed, they may have worse outcomes. There is also evidence that the response to several pharmacologic therapies may differ between Black and White patients.
- Published
- 2023
- Full Text
- View/download PDF
49. Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial
- Author
-
Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Bhatt, Ankeet S, Lee, Simin Gharib, Modin, Daniel, Claggett, Brian L, Dueger, Erica L, Samson, Sandrine I, Loiacono, Matthew M, Køber, Lars, Solomon, Scott D, Sivapalan, Pradeesh, Jensen, Jens Ulrik Stæhr, Martel, Cyril Jean-Marie, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor
- Abstract
Influenza vaccination rates remain suboptimal despite effectiveness in preventing influenza infection and related complications. We investigated whether behavioural nudges, delivered via a governmental electronic letter system, would increase influenza vaccination uptake among older adults in Denmark.
- Published
- 2023
- Full Text
- View/download PDF
50. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes
- Author
-
Inciardi, Riccardo M., Giugliano, Robert P., Park, Jeong-Gun, Nordio, Francesco, Ruff, Christian T., Chen, Cathy, Lanz, Hans-Joachim, Antman, Elliott M., Braunwald, Eugene, and Solomon, Scott D.
- Abstract
The risks of heart failure (HF) events compared with stroke/systemic embolic events (SEE) or major bleeding (MB) in heart failure with reduced ejection fraction (HFrEF) vs heart failure with preserved ejection fraction (HFpEF) in a large atrial fibrillation (AF) population have not been well-studied.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.